Endogenous Neurotoxins {#sec1-1}
======================

The role of environmental factors and genetic predisposition in Parkinson\'s disease has been discussed for a long time. The average time of normal onset in idiopathic Parkinson\'s disease is around 60 years old. However, one of the most relevant features of Parkinsonism induced by environmental factors such as manganese, copper and pesticides (paraquat), is the early onset observed in young people exposed to these contaminants. The familial form of the disease induced by a gene mutation (alpha-synuclein, parkin, DJ-1, PINK-1, LRRK-2, ATP13A2, PINK-1 and others) also has early onset in young people. The exposure of humans to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced an extremely rapid Parkinsonism in just 3 days, with the subjects developing severe motor symptoms, suggesting that exogenous neurotoxins cannot play a role in the idiopathic form of the disease. The degeneration of dopaminergic neurons containing neuromelanin in the nigrostriatal system initiates years before the motor symptoms are evident. The rate of the degenerative process in both Parkinsonism induced by contaminants, and familial Parkinson\'s disease is significantly more rapid, explaining its early onset in young people (Segura-Aguilar and Kostrzewa, 2015). Therefore, the degeneration of the nigrostriatal system seems to involve an endogenous neurotoxin. Possible sources of endogenous neurotoxins are.

Neurotoxins generated during dopamine oxidation to neuromelanin {#sec2-1}
---------------------------------------------------------------

The role of dopamine oxidation to neuromelanin in the loss of dopaminergic neurons containing neuromelanin in the nigrostriatal system in the idiopathic Parkinson\'s disease seems to play a key role. Dopamine oxidizes to neuromelanin by generating *ortho(o)*-quinones in a sequential manner that finally polymerize to neuromelanin (dopamine → dopamine *o*-quinone → aminochrome → 5,6-indolequinone → neuromelanin). However, these *o*-quinones can be neurotoxic under certain conditions: (i) Dopamine *o*-quinone: Dopamine *o*-quinone is stable under pH2 and at physiological pH cyclizes immediately at a rate of s^--1^. In isolated mitochondria, dopamine *o*-quinone forms adducts with proteins such as ubiquitin C-terminal hydrolase-L1 (UCH-L1), isocitrate dehydrogenase, complex I, III and V, superoxide dismutase-2, Parkinson protein 7 (DJ-1), actin gamma, mitochondrial creatine kinase, mitochondrial voltage-dependent anion channel 1, heat shock protein 60, mortalin/GRP75/mtHSP70 and other proteins. However, in SH-SY5Y cells dopamine *o*-quinone forms adducts only with UCH-L1, DJ-1, mortalin/GRP75/mtHSP70 and actin. Dopamine *o*-quinone forms adducts with the dopamine transporter. Other studies showed that dopamine oxidation\'s products forms adducts with parkin, and tyrosine hydroxylase and the question is, which *o*-quinone was involved (dopamine *o*-quinone or aminochrome). In the case of parkin it seems that dopamine *o*-quinone was not involved in parkin-dopamine adduct formation in cells, while in tyrosine hydroxylase adducts it is possible that dopamine *o*-quinone was responsible, because the reaction was performed with purified tyrosine hydroxylase with dopamine and tyrosinase. (ii) The compound 5,6-indolequinone forms adducts with alpha-synuclein. (iii) Dopaminochrome forms adducts with alpha-synuclein, and induces neurotoxicity in cell lines and degeneration in substantia nigra, but the structure of this *o*-quinone has not been determined. (iv) Aminochrome is the most stable *o*-quinone formed during dopamine oxidation to neuromelanin and also the most studied. Aminochrome has been reported to be neurotoxic by inducing mitochondria dysfunction, aggregation of alpha-synuclein to neurotoxic oligomers, protein degradation dysfunction, disruption of cytoskeleton architecture, neuroinflammation, and oxidative and endoplasmic reticulum stress in cells (oxidative stress: Segura-Aguilar et al., 1998; Arriagada et al., 2004; Zafar et al., 2006; Fuentes et al., 2007; Paris et al., 2010, 2012; Aguirre et al., 2012; Muñoz et al., 2012a, b, 2015; Huenchuguala et al., 2014; Xiong et al., 2014; Briceño et al., 2015; Muñoz and Segura-Aguilar, 2017b; Santos et al., 2017). Intracerebral injection of aminochrome into the striatum induces a progressive neuronal dysfunction as a consequence of mitochondrial dysfunction, decrease of dopamine release, disruption of monoaminergic vesicles' axonal transport and increased GABA level (**[Figure 1](#F1){ref-type="fig"}**; for review see Segura-Aguilar et al. (2014, 2016) and Herrera et al. (2017).

![Neurotoxic mechanism of endogenous neurotoxins.\
Free dopamine in the cytosol can (i) oxidize to neurotoxic *o*-quinones (dopamine *o*-quinone, aminochrome and 5,6-indolequinone) or (ii) be degraded by monoamine oxidase to DOPAL that can be neurotoxic when it accumulates. ALDH-1: Aldehyde dehydrogenase 1; DOPAL: 3,4-dihydroxyphenylacetaldehyde; ER: endoplasmic reticulum; NADH: nicotinamide adenine dinucleotide.](NRR-12-897-g001){#F1}

Another possible endogenous neurotoxin is alpha-synuclein {#sec2-2}
---------------------------------------------------------

Alpha-synuclein oligomers: (i) inhibit autophagy, (ii) induce disruption of the endoplasmic reticulum and Golgi traffic, (iii) induce mitochondrial dysfunction, (iv) inhibit proteasomal activity, (v) increase oxidative stress and (vi) induce neuroinflammation by activating microglia and increasing proinflammatory cytokines and nitric oxide (**[Figure 1](#F1){ref-type="fig"}**; for review see Muñoz and Segura-Aguilar, 2017). However, the question is, what induces alpha-synuclein aggregation to neurotoxic oligomers in the sporadic form of Parkinson\'s disease? It has been suggested that alpha-synuclein oligomers can be released from the neuron, thus propagating its neurotoxic action. The prion-like hypothesis for alpha-synuclein-induced disease progression is based on the release of many copies of alpha-synuclein oligomers into the synaptic cleft, so that the surrounding neurons and glial cells are able to internalize these alpha-synuclein oligomers. The propagating action of alpha-synuclein should be a rapid process contrasting with the extremely slow progression of Parkinson\'s disease.

3,4-Dihydroxyphenylacetaldehyde (DOPAL) {#sec2-3}
---------------------------------------

Free cytosolic dopamine oxidizes to neuromelanin generating *o*-quinones that can be neurotoxic under certain conditions. However, dopamine stored in monoaminergic vesicles is completely stable due to the relatively low pH generated by an ATPase that pumps protons into the monoaminergic vesicles. Dopamine synthesis is performed in the cytosol but the enzymes involved in dopamine synthesis form a kind of complex with the vesicular monoamine transporter-2 (VMAT-2), bound to the monoaminergic vesicles membrane, preventing the existence of free dopamine (**[Figure 2](#F2){ref-type="fig"}**; for review see Segura-Aguilar et al., 2014). The other source of free dopamine is the reuptake of dopamine released under neurotransmission, but VMAT-2 can take up dopamine into monoaminergic vesicles. However, monoamine oxidase catalyzes the oxidative deamination of dopamine in order to degrade dopamine to DOPAL with the concomitant formation of hydrogen peroxide. DOPAL is oxidized to 3,4-dihydroxyphenylacetic acid (DOPAC) which can be converted to homovanillic acid by catechol ortho-methyltransferase. Dopamine degradation to homovanillic acid depends on the normal level of expression of aldehyde dehydrogenase that catalyzes the oxidation of DOPAL to DOPAC. In the human substantia nigra two genes of aldehyde dehydrogenase 1 and 2 are expressed in cytosol and mitochondria respectively, but only aldehyde dehydrogenase-1 was found to be decreased in Parkinson\'s disease (Goldstein et al., 2014). Gene expression studies performed with post-mortem material from substantia nigra of Parkinson\'s disease patients and controls, revealed a significant decrease in aldehyde dehydrogenase-1 (Grünblatt et al., 2004). The low expression of aldehyde dehydrogenase-1 will lead to the accumulation of DOPAL and subsequent toxic effects by inducing oxidative stress and the formation of adducts with proteins (**[Figure 1](#F1){ref-type="fig"}**; for review see Goldstein et al. (2014)). DOPAL has been reported to induce the formation of alpha-synuclein oligomers suggesting a role in Parkinson\'s disease (Follmer et al., 2015). However, it is necessary to regard the results obtained with post-mortem material with caution, because the low expression of this enzyme determined in substantia nigra correspond to the surviving neurons and not neurons which have undergone degeneration probably years before. In addition, patients with low expression of aldehyde dehydrogenase-1 should develop the disease with early onset, but we know that the average age for the idiopathic form of Parkinson\'s disease is 60 years old.

![Cellular protection of dopaminergic neurons containing neuromelanin.\
VMAT-2 prevents the existence of free dopamine in the cytosol by taking up dopamine from the reuptake mediated by dopamine transporter and dopamine synthetized from tyrosine. In the case that dopamine is free in cytosol it can be degraded by monoamine oxidase to DOPAL and later to DOPAC by aldehyde deshidrogenase-1. Alternatively, dopamine oxidizes to aminochrome but the enzymes DT-diaphorase and GSTM2 prevent aminochrome-induced neurotoxicity. DOPAC: 3,4-Dihydroxyphenylacetic acid; DOPAL: 3,4-dihydroxyphenylacetaldehyde; GSTM2: glutathione transferase M2-2; VMAT-2: vesicular monoamine transporter-2.](NRR-12-897-g002){#F2}

Endogenous Neuroprotection {#sec1-2}
==========================

VMAT-2 {#sec2-4}
------

The first neuroprotective mechanism is mediated by VMAT-2 located in the membrane of monoaminergic vesicles. VMAT-2 takes up dopamine into the monoaminergic vesicles where dopamine is stable and accumulates to be used for neurotransmission. VMAT-2 prevents the existence of free cytosolic dopamine which participates in oxidizing reactions such as dopamine oxidation during neuromelanin formation with concomitant formation of neurotoxic *o*-quinones. The level of VMAT-2 expression is inversely correlated with the level of neuromelanin in dopaminergic neurons (Liang et al., 2004). Interestingly, monoaminergic vesicles isolated from Parkinson\'s disease patients revealed that both dopamine uptake and the binding of VMAT-2 inhibitor were significantly reduced in comparison to control brains (Pifl et al., 2014). VMAT-2 also prevents dopamine oxidative deamination catalyzed by monoamine oxidase to DOPAL.

DT-diaphorase {#sec2-5}
-------------

DT-diaphorase is a flavoenzyme that catalyzes the two-electron reduction of aminochrome to leukoaminochrome. DT-diaphorase prevents aminochrome-induced: (i) formation of neurotoxic α-synuclein oligomers; (ii) cell death; (iii) mitochondria dysfunction; (iv) inhibition of the proteasomal system; (v) inhibition of autophagy/lysosomal system; (vi) inhibition of α- and β-tubulin aggregation and disruption of cytoskeleton architecture; (vi) inhibition of oxidative stress; and (vii) cell shrinkage (Arriagada et al., 2004; Fuentes et al., 2007; Lozano et al., 2010; Paris 2010, 2011; Muñoz et al., 2012a, b, 2015; Segura Aguilar et al., 2014, 2016; Huenchuguala et al., 2016; Herrera et al., 2017; Herrera-Soto et al., 2017; Muñoz and Segura-Aguilar, 2017). The inhibition of DT-diaphorase *in vivo* induced the loss of dopaminergic neurons in animals intracerebrally injected with aminochrome (Herrera et al., 2017). This enzyme is constitutively expressed both in dopaminergic neurons, where *o*-quinones are formed during dopamine oxidation to neuromelanin, and in astrocytes that prevent aminochrome-induced toxicity.

Human glutathione transferase M2-2 (GSTM2) {#sec2-6}
------------------------------------------

GSTM2 catalyzes glutathione conjugation of both aminochrome and dopamine *o*-quinone to 4-S-glutathionyl-5,6-dihydroxyindoline and 5-S-glutathionyldopamine respectively (Baez et al., 1997; Segura-Aguilar et al., 1997; Dagnino-Subiabre et al., 2000). The compound 4-S-glutathionyl-5,6-dihydroxyindoline is stable in the presence of biological oxidizing agents such as oxygen, hydrogen peroxide and superoxide radicals, suggesting a protective role for this reaction. The compound 5-S-glutathionyldopamine is finally degraded to 5-S-cysteinyldopamine, which has been detected in the neuromelanin, substantia nigra, putamen, caudate nucleus, globus pallidus, and the cerebrospinal fluid of Parkinson\'s disease patients, suggesting that this conjugate is an end-product. GSTM2 is expressed only in astrocytes but this enzyme protects both astrocytes and dopaminergic neurons against aminochrome toxicity. Astrocytes protect dopaminergic neurons by secreting GSTM2 which is internalized into dopaminergic neurons (Cuevas et al., 2015; Segura-Aguilar et al., 2015, 2016; Muñoz et al., 2016; Herrera et al., 2017).

Conclusions {#sec1-3}
===========

The role of environmental factors and genetic predisposition has been discussed for a long time in the idiopathic Parkinson\'s disease. However, both Parkinsonism induced by metals or pesticides, and the familial form of the disease induced by specific mutations, induce an early-onset form of Parkinson\'s disease contrasting with the normal onset at 60 years old of the idiopathic form of Parkinson\'s disease. Therefore, it seems to be plausible that the extremely slow degenerative process before the motor symptoms appear and also under the disease progression, depends on the formation of endogenous neurotoxins during dopamine oxidation to neurotoxic *o*-quinones, alpha-synuclein neurotoxic oligomers and DOPAL oxidation to an *o*-quinone. Interestingly, there are endogenous mechanisms to protect dopaminergic neurons which prevent the neurotoxic action of these endogenous neurotoxins, such as VMAT-2, DT-diaphorase and GSTM2.
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